Bank of New York Mellon’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Bank of New York Mellon’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-49,377	Closed	-$188K	–	4268
2019 Q3	$188K	Hold	49,377	–	–	﹤0.01%	3917
2019 Q2	$328K	Buy	49,377 +21,971	+80%	+$83.6K	﹤0.01%	3783
2019 Q1	$98K	Sell	27,406 -1,182	-4%	-$6.41K	﹤0.01%	4008
2018 Q4	$113K	Buy	28,588 +2,914	+11%	+$37.3K	﹤0.01%	3943
2018 Q3	$508K	Buy	25,674 +7,268	+39%	+$184K	﹤0.01%	3645
2018 Q2	$584K	Buy	18,406 +7,231	+65%	+$260K	﹤0.01%	3562
2018 Q1	$413K	Buy	11,175 +3,692	+49%	+$243K	﹤0.01%	3669
2017 Q4	$592K	Buy	+7,483	New	+$554K	﹤0.01%	3531

Other funds holding MLNT

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CCM

Condor Capital Management Martinsville, New Jersey $1.33B AUM 19.79% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Bank of New York Mellon's MLNT Position: Q4 2019 in Review

Bank of New York Mellon sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2019, closing a stake of 49,377 shares — an estimated $188K sold.

Bank of New York Mellon first reported a position in MLNT in Q4 2017 and held it in 8 quarters. The position peaked at $592K in Q4 2017. 37 funds tracked by Wall St. Rank hold MLNT as of Q4 2019.

Bank of New York Mellon reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Bank of New York Mellon sold 49,377 Melinta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $188K.
Bank of New York Mellon first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 8 quarters.
Bank of New York Mellon's Melinta Therapeutics, Inc. Common Stock position peaked at $592K in Q4 2017.
37 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Bank of New York Mellon's 13F filing for Q4 2019, filed 14 Feb 2020.